ESR1 and breast cancer: ER+ and/or PR+ tumors represent more than two-thirds of breast cancer cases and are currently treated with hormonal therapies that most commonly include aromatase inhibitors, which suppress endogenous estrogen production, or antiestrogens, which compete with estrogens for binding to estrogen receptors and inactivate them by inducing alternative conformations of their ligand-binding domains [4,5].